Analysts Set Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) PT at $12.33

Shares of Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) have earned a consensus rating of “Moderate Buy” from the five brokerages that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $12.3333.

Several analysts have recently issued reports on the stock. Jones Trading upgraded shares of Evaxion A/S to a “strong-buy” rating in a research report on Wednesday, October 29th. Edward Jones initiated coverage on Evaxion A/S in a research note on Thursday, October 30th. They set a “buy” rating and a $10.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Evaxion A/S in a research note on Monday, October 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Evaxion A/S in a report on Friday, January 9th. Finally, Lake Street Capital increased their price target on Evaxion A/S from $6.00 to $11.00 and gave the company a “buy” rating in a report on Monday, October 20th.

Evaxion A/S Stock Performance

Shares of EVAX opened at $4.18 on Thursday. The stock has a market capitalization of $34.86 million, a PE ratio of -10.72 and a beta of 0.29. The company’s fifty day moving average is $5.27 and its 200 day moving average is $4.47. Evaxion A/S has a fifty-two week low of $1.20 and a fifty-two week high of $12.15.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.